Mesenchymal Stromal Cells
Trials 36
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 115 trials | ||||||
| Phase 1 | NCT04489732 | Feb → Nov 2022 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT04467047 | Jul → Oct 2020 | COVID-19 | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 1 | NCT02574572 | Sep 2017 → Dec 2019 | spinal cord injury | Hospital Sao Rafael | Unknown | No outcome recorded |
| Phase 1 | NCT02565459 | Sep 2015 → Sep 2021 | chronic renal failure syndrome | Monia Lorini | Unknown | No outcome recorded |
| Phase 1 | NCT02387151 | Mar 2015 → Nov 2018 | transplant rejection | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02359929 | Jan 2015 → Jun 2020 | acute graft versus host disease, chronic graft versus host disease | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02260375 | Oct 2014 → Oct 2024 | transplant rejection | Monia Lorini | Unknown | No outcome recorded |
| Phase 1 | NCT02195323 | Apr 2014 → Dec 2015 | chronic kidney disease | Royan Institute | Completed | No outcome recorded |
| Phase 1 | NCT02215811 | Mar 2014 → Dec 2015 | adult acute respiratory distress syndrome | Karolinska University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02012153 | Dec 2013 → May 2023 | transplant rejection | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01759797 | Jan 2013 → Jan 2014 | amyotrophic lateral sclerosis | Royan Institute | Completed | No outcome recorded |
| Phase 1 | NCT01522716 | Aug 2011 → Mar 2016 | chronic graft versus host disease | Karolinska Institutet | Terminated | No outcome recorded |
| Phase 1 | NCT01275612 | Nov 2010 → Mar 2018 | acute kidney injury, cancer | Mario Negri Institute for Pharmacological Research | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01306513 | Oct 2010 → Jun 2012 | pulmonary emphysema | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01764100 | Sep 2009 → May 2013 | graft versus host disease | Ettore Biagi, MD | Unknown | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT03211793 | Oct 2021 → Nov 2026 expected | chronic ulcer of skin, systemic sclerosis | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04345601 | Feb 2021 → Jan 2023 | COVID-19, acute respiratory distress syndrome | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT04445454 | Jun 2020 → Sep 2024 | COVID-19 | University of Liege | Unknown | No outcome recorded |
| Phase 1/2 | NCT04400032 | May 2020 → Apr 2021 | COVID-19, acute respiratory distress syndrome | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT03901235 | Jan 2018 → Dec 2025 overdue | — | University of Liege | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02323789 | Jun 2015 → Jul 2017 | recessive dystrophic epidermolysis bullosa | King's College London | Unknown | No outcome recorded |
| Phase 1/2 | NCT02351011 | Feb 2015 → Dec 2018 | osteoarthritis, knee | Jas Chahal | Completed | No outcome recorded |
| Phase 1/2 | NCT02055625 | Jan 2014 → Aug 2019 | chronic graft versus host disease | Karolinska Institutet | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01849237 | Dec 2012 → Apr 2013 | infectious disease with sepsis, neutropenia | National Research Center for Hematology, Russia | Unknown | No outcome recorded |
| Phase 29 trials · 1 missed | ||||||
| Phase 2 | NCT05333029 | Oct → Dec 2024 | graft versus host disease | Molly Gallogly | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06146062 | Jun 2024 → Aug 2027 expected | traumatic brain injury | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT06163833 | Sep 2023 → Dec 2024 overdue | traumatic brain injury | Fondazione IRCCS San Gerardo dei Tintori | Recruiting | No outcome recorded |
| Phase 2 | NCT04615429 | Sep 2020 → Jan 2022 | acute respiratory distress syndrome, pneumonia | Cristina Avendaño Solá | Completed | Missed primary |
| Phase 2 | NCT04466098 | Jul 2020 → Feb 2022 | acute respiratory distress syndrome, pneumonia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT04918706 | Jun 2019 → Sep 2021 | pulmonary emphysema | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01589549 | Apr 2012 → Dec 2015 | acute graft versus host disease | R.P.Herrmann | Unknown | No outcome recorded |
| Phase 2 | NCT01090817 | Jan 2010 → Jun 2014 | Crohn disease | R.P.Herrmann | Completed | No outcome recorded |
| Phase 2 | NCT00957931 | Mar 2009 → Aug 2013 | Diamond-Blackfan anemia, sickle cell disease, thalassemia | Stanford University | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04247945 | Feb 2020 → Dec 2023 | disease related to hematopoietic stem cell transplant | Fujian Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02270307 | Jan 2014 → Jan 2016 | leukemia, plasma cell myeloma | National Research Center for Hematology, Russia | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06171906 | Jan 2024 → Oct 2025 overdue | — | ShiCang Yu | Not yet recruiting | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT06392711 Comparator | Oct 2024 → Nov 2028 expected | Sjogren syndrome, graft versus host disease | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 1 | NCT01061099 Comparator | Feb 2010 → Mar 2013 | osteogenesis imperfecta type 2, osteogenesis imperfecta type 3 | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05705024 Comparator | Sep 2023 → Sep 2026 overdue | corneal ulcer | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT02057965 Comparator | Mar 2014 → Jan 2020 | transplant rejection | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02913261 Comparator | Mar 2017 → Jun 2019 | acute graft versus host disease | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02291770 Comparator | Oct 2014 → Nov 2015 | chronic graft versus host disease | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-04 | CytoMed Therapeutics Pte Ltd | CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair cytomed.sg ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 50 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesenchymal stromal cells | “The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗41“we expect that ex-vivo expanded donor bone-marrow derived mesenchymal stromal cells (MSC) infusion would allow to accelerate tubular regeneration and thus renal function...” NCT01275612 ↗ “Patients with newly diagnosed untreated acute graft versus host disease grades 2-4 will receive methylprednisolone 2.5mg/kg intravenously and randomised to receive or not...” NCT01589549 ↗ “Objective: To determine whether patients with emphysema develop anti-inflammatory and tissue repair responses by treatment with allogeneic bone marrow-derived mesenchymal...” NCT04918706 ↗ “intravenous (IV) and intrathecal (IT) injections of bone marrow derived mesenchymal stromal cells (BM-MSCs) in patients with ALS.” PMID 30124008 ↗ Aug 2018 “Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)” NCT02195323 ↗ “Mesenchymal stromal cells (MSC) have been shown to improve neurological function following spinal cord injury.” PMID 39328312 ↗ Sep 2024 “Co-transplantation of Mesenchymal Stromal Cells in Allogeneic Hematopoietic Stem Cell Transplantation” NCT04247945 ↗ “Mesenchymal stromal cells (MSCs) are an ideal candidate” NCT06163833 ↗ “Mesenchymal Stromal Cells (MSCs)” NCT02351011 ↗ |
| Known as | BM-MSC | “Ten patients will be enrolled and receive allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSC).” NCT02215811 ↗ |
| Known as | BM-MSCs | “intravenous (IV) and intrathecal (IT) injections of bone marrow derived mesenchymal stromal cells (BM-MSCs) in patients with ALS.” PMID 30124008 ↗ Aug 20182“Bone marrow-derived mesenchymal stromal cells (BM-MSCs) are a viable cell-based therapy for xerostomia.” PMID 35183442 ↗ Feb 2022 “Autologous Bone Marrow Mesenchymal Stem Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)” NCT02195323 ↗ |
| Known as | Mesenchymal stem cells | “This is a pilot, explorative, study to test the feasibility and safety of systemic infusion of donor ex-vivo expanded Mesenchymal Stem Cells to repair the kidney and improve...” NCT01275612 ↗3“Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome...” NCT04247945 ↗ “This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic kidney disease (CKD).” NCT02195323 ↗ “Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function.” NCT04467047 ↗ |
| Known as | Mesenchymal Stromal Cells (MSCs) | “Mesenchymal Stromal Cells (MSCs)” NCT02351011 ↗ |
| Known as | MSC | “we expect that ex-vivo expanded donor bone-marrow derived mesenchymal stromal cells (MSC) infusion would allow to accelerate tubular regeneration and thus renal function...” NCT01275612 ↗8“Objective: To determine whether patients with emphysema develop anti-inflammatory and tissue repair responses by treatment with allogeneic bone marrow-derived mesenchymal...” NCT04918706 ↗ “Here, we report on 11 patients with severe, refractory cGvHD treated with repeated infusions of allogeneic bone marrow-derived mesenchymal stromal cells (MSC) over a 6- to...” PMID 32573983 ↗ Jun 2020 “Mesenchymal stromal cells (MSC) have emerged as a promising therapy to minimize the immunosuppressive regimen or induce tolerance in solid organ transplantation.” PMID 33370477 ↗ Feb 2021 “Mesenchymal stromal cells (MSC) have been shown to improve neurological function following spinal cord injury.” PMID 39328312 ↗ Sep 2024 “Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells” NCT01764100 ↗ “Mesenchymal stromal cells (MSC) for infusion” NCT01090817 ↗ “Mesenchymal Stromal Cells (MSC) Dose Level 0” NCT06392711 ↗ “Drug: Mesenchymal Stromal Cells (MSC)” NCT06146062 ↗ |
| Known as | MSC(M) | “interferon gamma (IFNγ)-stimulated autologous bone marrow-derived MSCs, or MSC(M), for the treatment of radiation-induced xerostomia (RIX).” PMID 37589639 ↗ Aug 2023 |
| Known as | MSCs | “Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome...” NCT04247945 ↗11“autologous bone marrow-derived mesenchymal stromal cells (MSCs) as part of a phase 1 study focused on the safety and feasibility of this cell therapy” PMID 29963053 ↗ Jun 2018 “The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow.” NCT05705024 ↗ “Mesenchymal stromal cells (MSCs), identified within the bone marrow stroma, are a type of non-hematopoietic multipotent stem cells.” NCT06171906 ↗ “This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic kidney disease (CKD).” NCT02195323 ↗ “mesenchymal stromal cells (MSCs) are an interesting candidate because of their immunosuppressive and regenerative properties.” PMID 23349326 ↗ Jan 2013 “Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function.” NCT04467047 ↗ “Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue repair in pulmonary emphysema.” PMID 26819296 ↗ Jan 2016 “autologous bone marrow-derived Mesenchymal Stromal Cells (MSCs)” NCT04489732 ↗ “Autologous mesenchymal stromal cells (MSCs)” NCT02359929 ↗ “Allogeneic mesenchymal stromal cells (MSCs)” NCT05333029 ↗ |
| Known as | TC-MSC | “TC-MSC: a cell product containing mesenchymal stromal cells.” NCT02323789 ↗ |
| Known as | UC-MSC | “repeated delivery of Umbilical Cord Mesenchymal Stromal Cells (UC-MSC) intravenously.” NCT04400032 ↗ |
| Known as | Umbilical Cord Mesenchymal Stromal Cells | “repeated delivery of Umbilical Cord Mesenchymal Stromal Cells (UC-MSC) intravenously.” NCT04400032 ↗ |
| Known as | WJ-UC-MSC | “repeated intravenous treatment with mesenchymal stromal cells derived from Wharton's Jelly of the umbilical cord-derived mesenchymal stromal cells ((WJ-UC-MSC) may be...” PMID 39740941 ↗ Dec 2024 |
| Modality | Cell therapy | “Mesenchymal stromal cells administered weekly for 4 weeks” NCT01090817 ↗ |
| Route | Intravenous | “MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks” NCT01090817 ↗ |